Twist Bioscience (TWST) CFO logs mandated tax sell-to-cover trade

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,019 shares of common stock at an average price of $53.257 per share. According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s equity incentive plans and were not discretionary trades. After this transaction, Laponis directly holds 116,675 shares of Twist Bioscience common stock.

Insider Trade Summary

Net Seller: 2,019 shares ($107,526)

Net Sell 1 txn

Insider Laponis Adam

Role Chief Financial Officer

Sold 2,019 shs ($108K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,019	$53.257	$108K

Holdings After Transaction: Common Stock — 116,675 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 2,019 shares Sale price: $53.257 per share Shares held after transaction: 116,675 shares

3 metrics

Shares sold 2,019 shares Open-market sale on 2026-05-21

Sale price $53.257 per share Average price for the 2,019 shares sold

Shares held after transaction 116,675 shares Direct holdings of CFO after sale

Key Terms

Restricted Stock Units, sell to cover, equity incentive plans, open-market sale

4 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"mandated by the Issuer's election under its equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		S		2,019(1)	D	$53.257	116,675	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Twist Bioscience (TWST) CFO Adam Laponis report in this Form 4?

Twist Bioscience CFO Adam Laponis reported selling 2,019 shares of common stock at $53.257 per share. The shares were sold to cover tax withholding obligations from restricted stock unit vesting mandated under the company’s equity incentive plans.

Why did Twist Bioscience (TWST) CFO sell 2,019 shares in this filing?

The 2,019 shares were sold to satisfy tax withholding obligations arising from vesting of restricted stock units. The filing states these “sell to cover” trades are mandated by Twist Bioscience’s equity incentive plans and are not discretionary investment decisions by the CFO.

How many Twist Bioscience (TWST) shares does the CFO hold after this transaction?

After the reported transaction, CFO Adam Laponis directly holds 116,675 shares of Twist Bioscience common stock. This post-transaction holding figure is disclosed in the Form 4 and shows his remaining equity position following the tax-related share sale.

Was the Twist Bioscience (TWST) CFO’s share sale a discretionary trade?

The filing states the sale was not discretionary. It explains the 2,019 shares were required to be sold under Twist Bioscience’s equity incentive plans to cover tax withholding from restricted stock unit vesting, described as a mandated “sell to cover” transaction.

What price did Twist Bioscience (TWST) CFO receive per share in this Form 4 sale?

The CFO’s reported sale of 2,019 Twist Bioscience common shares was executed at an average price of $53.257 per share. This price is disclosed in the Form 4 and applies specifically to the tax-related “sell to cover” transaction described in the footnote.